Metraipolis › archive › dc_d883ccb3e8a4

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib — Europe PMC PMID:40839414

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40839414
DOI
10.1002/cncr.70062
License (as archived)
solo-consultazione
Archived
2026-11-10T05:02:48.555Z
SHA-256 of the archived text
ed75f679ba0a1eb1bc760bf053817d201e22f5e9ef256dac4395cadb72822023
Stable URL of this page
https://metraipolis.com/documento/dc_d883ccb3e8a4

How to cite

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib — Europe PMC PMID:40839414 — Europe PMC (en), https://europepmc.org/article/MED/40839414 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d883ccb3e8a4 (Metraipolis archive dc_d883ccb3e8a4, sha256 ed75f679ba0a1eb1bc760bf053817d201e22f5e9ef256dac4395cadb72822023)
BibTeX
@misc{dcd883ccb3e8a4,
  title = {Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib — Europe PMC PMID:40839414},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40839414},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d883ccb3e8a4; sha256 ed75f679ba0a1eb1bc760bf053817d201e22f5e9ef256dac4395cadb72822023},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40839414. Agents can read the archived copy with the MCP tool read_document.